Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
J.
Roderick (Rod) Matheson, Chief Executive Officer Email: [email protected] Dr.
Mark Williams, President and Chief Science Officer Email: [email protected] Tel: 403 770 2469 Website: www.marvelbiotechnology.com | Twitter/X | LinkedIn Read More
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.